A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis

PURPOSE: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors afford symptom and spleen burden reduction but do not alter the disease course and frequently lead to thrombocytopenia. TGFβ, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascarenhas, John, Migliaccio, Anna Rita, Kosiorek, Heidi, Bhave, Rupali, Palmer, Jeanne, Kuykendall, Andrew, Mesa, Ruben, Rampal, Raajit K., Gerds, Aaron T., Yacoub, Abdulraheem, Pettit, Kristen, Talpaz, Moshe, Komrokji, Rami, Kremyanskaya, Marina, Gonzalez, Agapito, Fabris, Frank, Johnson, Kathryn, Dougherty, Mikaela, McGovern, Erin, Arango Ossa, Juan, Domenico, Dylan, Farnoud, Noushin, Weinberg, Rona Singer, Kong, Amy, Najfeld, Vesna, Vannucchi, Alessandro Maria, Arciprete, Francesca, Zingariello, Maria, Falchi, Mario, Salama, Mohamed E., Mead-Harvey, Carolyn, Dueck, Amylou, Varricchio, Lilian, Hoffman, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502472/
https://www.ncbi.nlm.nih.gov/pubmed/37439808
http://dx.doi.org/10.1158/1078-0432.CCR-23-0276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502472/
https://www.ncbi.nlm.nih.gov/pubmed/37439808
http://dx.doi.org/10.1158/1078-0432.CCR-23-0276

Ejemplares similares